We studied the effect of antileukotriene therapy for the relief of sinus sympto ms in patients with aspirin triad disease (ATD ) 
Introduction
Aspi rin triad disea se (AT O) is a chronic infl ammatory process that is associated with asthma, aspirin intolerance, and nasal pol yposis.I ATO patients often com e to otolaryngo logy clinics for management ofsinonasa l co mplaints.
Leuk otri ene s contribute to the pathogene sis of aspirin intolerance and asthrn a.!? Th e triggerin g of ATO by as pirin or by non st eroidal anti-infl amma tory dru gs 
604
(NSAIDs) is very selecti ve and rare. Th e mechanism of this phenomenon is not known. Leukotrienes are the breakdown products of arachidonic acid metabolism . Arach idonic acid is metaboli zed to prostaglandins, leuk otr ien es , a nd e po xye icos a tr ie no ic acid by cyclooxygenase, lipoxygenase, and epoxygenase , respectively. When an aspirin produ ct is taken by an ATO patient , the first two of these path ways are affected . Aspirin competitive ly bind s to the platelet surface, thus inhibiting the activi ty of cyclooxygena se and the production of prostaglandins and thrombox ane. Thi s free s up large amounts of arachidonic acid.' At the same tim e, aspirin stimulates 5-lipoxygen ase activity, most likely in the mast cell s, which lead s to a rapid production of leukotrienes." Leukotrienes cau se bronchocon str iction, increased mucu s secretion, and vascul ar perrneability.i" and they inhib it ciliary activity."
Overproduction of leukotrienes accounts for the abnormaliti es of ATO. 4 The recently devel oped antileukotriene agent s montelukast'? and zafirlukast" act as leukotriene recepto r antagoni sts , whil e zileuton12.13acts as a leukotriene synthes is inhibitor. All th ree dru gs diminish the effect s of leukotrienes in asthma patients (figure I) .
Antil euk otri ene the rapy dimin ishes the nasal respon se to as pirin and allerge n cha lle nge in patients with aspirinsensitive asthma" and allerg ic rhinitis. " Ho wever , the effect of antileukotriene therapy on sinonasal symptoms in ATO pat ient s has not been investigated. Th e purpose of this study was to det ermine the role of antileukotriene therapy in the relief of sinus sy mpto ms in patients with AT O.
Materials and methods
We retros pectively review ed the charts of all ATO patient s enrolled in the otol aryn gology clinic at the Medical College of Wi scon sin wh o had received antileukotriene therapy. Patients were evaluated by three methods: symptom scores, subjective self-reports, and nasal endoscopy. CK' S tw Earplugs are:
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Results
Subjects.
We identified 18 patients with ATD who had received antileuko triene therapy. The 6 men and 12 women were aged 30 to 70 years (mea n: 48 ± 3). Followup inform ation was ava ilab le on 15 of the 18. A diagnosis of ATD was based on the patient' s history of aspirin intolerance, asthma, and nasal polyposis. All patient s had a history of nasal and/or asthma symptoms following aspirin intake . Followin g their diagno sis, all patients had strictly avo ided aspirin and NSAID s, but all had persistent sym ptoms of chro nic rhinosinusitis despite medical and surgical therapy.
The duration of sinus disease in the 18 patients ranged from 2 to 26 years. Patients recognized their intolerance to aspirin after chronic rhinosinusitis and asthma developed.All patients had previously undergone paranasal sinus surgery: bilateral ethmoidectomy in 18, maxillary antrostomy in 15, sphenoidotomy in 14, osteop lastic flap with fat obliteration in three, and a modified endoscopic Lothrop procedure in one (table I) . Even so, symptoms of chro nic rhinosinu sitis persisted after surgery. 
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Aspiri n c:> Cyclooxvge nuseF igure 1. Site of the effec t of antileukotriene agents on arachidonic acid metabolism.
A questionnaire was used to obtain the infor mation on symptom scores and self-rati ngs.
The questionnaire was designed to assess the response to antileukotriene therapy and to determine the numb er of co morbid factors in eac h patient (figure 2). The questionnaire asked speci fic questions about eac h patient ' s general health and the effec t of antileukotriene therapy on their sinus disease. In the general health section, questions conce rned the personal and family medical history, alcohol and smoking habit s, history of allergy, and duration of ATD. The effec t of antileuko triene therapy on symptoms was evaluated by analyzi ng the answers to the Pt. specific questions regarding the degree of chronic rhinosi nusitis and the overa ll ben efit fro m antileukotriene therapy.
Patients reported the level of each major symptom (facial pain/press ure, facial conges tio n/fullness, nasal blockage, runn y nose, and impaired sense of smell) and minor symptom (sinus headache, halitosis, fatigue, tooth pain , cough, and ear pain/fullness) before and after antileukotriene therapy. The degree of eac h symptom was quantified as a symptom score: 0 points for no symptoms, I point for mild symptoms, 2 points for moderate symptoms, and 3 point s for severe symptoms. For each patient, major and minor symptom scores were added together to arrive at a total symptom score. To subjective ly determin e the overall benefit of antile uko trie ne therapy, patient s were asked to descr ibe their improvement as either none, slight, mode rate, or very good. An objective assess ment of the effect of antileukotriene therapy was based on the findings of an endosc opic nasal exa mination , .
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All were negativeapart fromthein vitromouse lymphoma assay where weak activity was found at very high, cytotoxic concentrations. Impainnent of Fertility: Augmentin at oral doses of up to 1200 mg/kg/day (5.7 times the maximum human dose, 14BO mg/m' /day, basedonbodysurfacearea) was found to have no effecton fenility and reproductive perf ormance in rats dosedwith a 2:1 ratio formulation of amoxicillin:clavulanate. Teratogeoic ellects: Pregnancy (Category B): Reproduction studies performed in pregnant rats and mice given Augme ntin at oral dosages up to 1200 mg/kg/day, equivalent to 7200 and 4080 mg/m' /day, respectively 14.9 and 2.Btimes the maximum human oral dose basedon body surfacearea), revealed no A ntileukotriene therapy. Anti leukotriene therapy consisted of ei ther the le ukotriene receptor an tagonis t zafirlukast at 20 mg twice a day or the 5-lipoxygenase inhibitor zileu ton at 600 mg four times a day. During antileukotriene therapy, patie nts did not receive any antibiotics or nasal decongestants. All patients continued to take their medications for asthma. Six teen of the 18 patients had taken zafirlukast, and the other two had take n z ile uto n. The duratio n of antileukotriene therapy ranged from I to IS mo nths . Two patients reported adverse effects from zafirlukast (nauVolume 78 , Number 8 DATE _ sea); one of these patien ts did not contin ue therapy, while the other was switched to zileuton. One patient on zileuton experience d side effects (nause a, right upper quadrant abdominal pain) and was switched to zafirlukast.
ANTILEUKO TRIENE THERAPY FOR THE RELIEF O F SIN US SYM PTOMS IN AS PIRIN TRIAD DISEASE
LIST OTHER MEDICATIONS DUR ING ACCO LATE
Questionnaire. Fifteen of the 18 patients filled out the questionnaire. None of the patients reported a family his tory of ATD, aspiri n into lerance, asthma, or nasal polyposi s. Four patient s had a histo ry of surgery other tha n sinus surgery (hysterectomy, coronary artery bypass, tonsillectomy, appendectomy) . Heartburn was reported by eight patients, thyroid disorders by three, depression Table 2 . Findings on pre-and posttreatment nasal endoscopy, and self-reported benefits of antileu kotriene therapy hibited at least one of the following symptoms: muco sal edema or erythema, mucoid or purulent nasal discharge, polypoid lesions, and nasal crusting (table 2) . Of the 15 patients, 11 underwent a posttreatment endoscopic nasal examination before they completed the questionnaire. At the time of the posttreatment endoscopic nasal examination , the duration of therapy had ranged from 1 to 12 by three, arthritis by three, and diabetes by one . A history of allergies to drugs was reported by eight patients, allergies to dust mites by three, and allergies to moldpollen-grass by two . None of the patients was currently a smoker; five were former smokers, whose duration of smoke-free status ranged from 5 to 25 years.
The 15 patients who completed the questionnaire reported the level of their chronic rhinosinusitis symptoms before and after antileukotriene therapy (table 2) . Major-symptom scores were significantly lower after antileukotriene therapy (range: 1-10; median: 5) than before Pt. treatment (range: 3-14; median: 8) (p=0.008) ( figure 3) . Similarly, minorsymptom scores were significantly lower after antileukotriene therapy (range: 0-10; median: 5) than before therapy (range: 0-17; median: 6) (p=0.01) (figure 4) .
Overall benefit from antileukotriene therapy was reported by 12 of the 15 patients; benefit was judged to be slight by seven patients, moderate by two, and very good by three ( 
Discussion
The ass ociation of aspirin intolerance, asthma, and nasal pol ypo sis is well recognized," :" and our findings are compatible wi th these earlier reports. In the pre sent study, mo st of the patients with ATD we re women, and they had all three components of ATD. No patient reported a family history of aspirin intolerance; aspirin intolerance was frequently recognized after the patient had been diagnosed with chronic rhinosinusitis and asthma. Leukotriene synthes is ha s been implicated in the pathogenesis of ATD. Elevated ba sal leukotriene level s hav e been found in aspirin-se nsitive pati ent s, and during as pirin-induced reactions further elevations in leukotriene E4 levels have been documented.s-" Leukotrienes were also found in the nasal secretions of patient s with aspirin sen sitivity after aspirin challenge. " During the aspirininduced nasal reactions, mast cell s and eosinophils were also activated in aspirin-se nsi tive patients.' :" Both mast ce lls and eosinophils are a so urce of leukotrienes. An increased number of eosinophils ha s been found in nasal polyps of aspirin-sensitive patients with asthma."
Treatment with aspirin during aspirin de sen siti zati on has been reported to lower the lev el of leukotriene C4 in nasal lav age fluid of as pirin-sensitive patients." Aspirin de sensitizati on treatment has also reduced the number of sinus surgeries and has improved olfaction." Although some studies have found that pati ent s with ATD had poor outcomes afte r sinus surgery,1.27 thi s is believed to be attributable to the adv anced stage of sinus dise ase in those patients." Patients with ATD have also been reported to have a high risk for nonoperativ e complications of chronic rhinosinu siti s.l -" Therefore, clo se long-term followup and intense medical management of chronic respiratory inflammation has been recommended. ' Recently developed antileukotriene agents can inhibit the effect s of leukotrien es. Antileukotriene agents have been shown to reduce nasal symptoms' :" and leukotriene levels in lavage fluid ":" after aspirin challenge. Pre viou s studies of aspi rin-sen sitive asthma patients have al so shown that antileukotriene agents attenuate asthma-associated bronchoconstri ction."
The safety of several antileukotriene age nts has been studied in clinical trials . The frequ ency of adverse events such as headache, gas tritis, pharyngiti s, and rhinitis wa s similar between zafirlukast-treated patients and placebo controls." Clinically silent elevated liver enzymes have been reported in zileuton-treated patients." Nau sea , mild lower abdo minal pain , and stomachache have also be en reported in z i leutori-treated patients. P Re cently , montelukast ha s been shown to be beneficial in asthmatic
Volume 78, Number 8 adults":" and in 6-to l-t-year-old asthmatic children, with out cau sing significa nt adverse effects or elevating liver en zym e levels.' ?
In the present study, we retrospecti vely evaluated the effect of antileukotriene ther apy on the relief of sinu s symptoms in a group of patients with ATD. Our study sho wed th at prior to antileukotriene ther apy, all ATD patient s continued to experience persistent symptoms of chronic rhinosinu sitis despit e havin g undergone sinus surge ry. Th e benefit of antil eukotriene the rapy wa s determined by patient self-reports and by endoscopi c nasal exa minations durin g the most recent followup visit. Scores for both major and minor sy m pto ms of ch ro nic rhinosinusiti s improved significantly after antileukotriene therapy . Mo st ATD pati ent s reported an overall benefit from the rapy. How ever, three pat ients who reported an overall benefit from therapy did not have a corresponding improvement in their symptom scores . On e plausible ex planation for thi s might be that our questionnaire wa s not sensitive enough to detect minor cha nges in the degree of symptoms . The self-reported effect s of sinu s disease on daily activities and on general he alth were also allevi ated
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